This financing removes near-term dilution risk and extends runway through commercialization. The Phase 2 data readout and Blackstone's endorsement are strong catalysts. Monitor the 8:00 a.m. ET webcast for APEX Part B efficacy/safety details and any updates on Phase 3 timeline.
Price Chart
Executive Summary
Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, including up to $800 million in synthetic royalty funding and up to $500 million in senior corporate debt. Combined with its existing $1.3 billion cash, this positions Apogee to fund Phase 3 development and potential commercialization of zumilokibart without future equity financing. The deal is the largest royalty financing for a pre-Phase 3 program and was announced alongside APEX Phase 2 Part B data.
Key Financial Metrics
Key Facts
- Up to $1.3 billion in non-dilutive capital from Blackstone Life Sciences, including up to $800 million synthetic royalty and up to $500 million senior corporate debt.
- First $400 million preapproval funding: $100M at signing, $100M upon Phase 3 enrollment completion, $200M upon positive Phase 3 data.
- Up to $400 million additional funding available upon FDA approval, $150M at Apogee's option.
- Royalty term of 15 years on worldwide annual sales of zumilokibart, with no royalties on global annual sales exceeding $8 billion.
- Company removing its cash runway end date guidance, citing self-sustainable financial profile through commercialization without future equity financing.
- Apogee currently has $1.3 billion in total cash.
- Goldman Sachs served as exclusive financial advisor to Apogee.
Financial Impact
Up to $1.3 billion in non-dilutive capital, with $100 million received at signing. Combined with existing $1.3 billion cash, total pro-forma liquidity exceeds $2.6 billion.
Risk Factors
- Phase 3 data may not meet expectations, jeopardizing milestone payments and approval.
- Royalty obligation reduces future revenue per dollar of sales.
- Senior debt (up to $500M) adds leverage if drawn.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301723 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access